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ABSTRACT 





tosylhydrazonates 1 and aliphatic diamine. It affords a number of bis-triazolones 2a-n  in reasonable yields. The structures 




C NMR studies as well as elemental analysis. Some of 
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INTRODUCTION  
The synthesis of bis-heterocyclic compounds has received considerable attention as it demonstrates a broad 
spectrum of biological activities such as anticancer, antibacterial, anti-tumor, and anti-mycobacterial activities [1-10]. 
Among these compounds, we can mention the bis-triazoles derivatives [11-15]. 
Various methods of the synthesis of 1,2,4- triazolones have been described in the literature [16-18]. Recently, the 
synthesis of Bis-triazolones, yielded by the reaction of bis-amidrazones with ethyl chloroformate has been illustrated [19]. 





-tosylhydrazonates 1 with diamine derivatives. 





-tosylhydrazonates 1a-b, used in this study, were prepared by the addition of N
1
-
















1a: R= CH3; 1b:R= C2H5
Scheme 1: Synthetic route to N1-ethoxycarbonyl N1- tosylhydrazonate 1a-b  
These compounds have two electrophilic centers at positions 1, 4 that are very reactive compared with compounds 
containing a nucleophilic center (e.g., diamines). 




-tosylhydrazonates 1a-b in ethanol with one equiv. 
of diamine derivatives, in the presence of a catalytic amount of glacial acetic acid produced, with a good yield, a cyclized 


















C NMR) data. The characterisation data of all new compounds is presented in the experimental section.  The 
IR spectra of compounds 2 shows absorption bands in the range of 1590-1610 cm
-1
, which are attributed to the C=N 
group. However, carbonyl stretching vibration bands are found to appear at around 1735cm
-1
. The NMR spectrum of 2 




-tosylhydrazonates 1. It 
also illustrates the presence of the characteristic resonance signals of protons introduced by the diamine derivatives. The 
13
C NMR signal for the C=O group is observed at around 151 ppm, whereas the signal of the C=N group is noted at 


























Scheme 2:Synthetic route to bis-triazolones 2 a-n
2a: R=CH3, Y=(CH2)3 ;2b:R= C2H5, Y= (CH2)3
2c:R= CH3, Y= (CH2)4 ; 2d: R= C2H5, Y= (CH2)4
2e:R= CH3, Y= (CH2)6 ; 2f:R= C2H5, Y= (CH2)6
2g:R= CH3, Y= (CH2)8 ; 2h:R= C2H5, Y= (CH2)8
2i:R= CH3, Y= (CH2)10 ; 2j:R= C2H5, Y= (CH2)10
2k:R= CH3, Y= (CH2)12 ; 2l:R= C2H5, Y= (CH2)12
2m:R= CH3, Y= (C6H10) ; 2n:R= C2H5, Y= (C6H10)
ISSN 2321-807X 
2179 | P a g e                                                           J u n e  0 9 ,  2 0 1 4  
Some of these compounds have already been synthesized from the condensation of bis-amidrazones with ethyl 
chloroformate as described above[19]. Given the substantially reduced number of bis-amidrazones, the synthesis 
presented in this paper is found to be advantageous following a more general and lower-cost approach. Furthermore, the 
proposed method is also proven to have better yields than the others. 
CONCLUSION 
The present research study reports the success of a novel strategy in the synthesis and characterization of new 
1,Y-bis(5-alkyl-2-tosyl-1,2,4-triazol-3-one-4-yl) alkane derivatives in good yields. 
EXPERIMENTAL  
The melting points were determined by Electrothermal 9100 apparatus. The infrared spectra were determined on a 
Perkin Elmer Spectrum Version 10.00.00 with a precision of 2 cm
-1
 covering field 400-4000 cm
-1
. NMR spectra were 
recorded in CDCl3 or in DMSO-d6 on a Bruker Avance spectrometer (400 MHz for 
1







chemical shifts are given on the δ scale (ppm) and referenced to internal T.M.S. The multiplicities of the signals are 
indicated by the following abbreviations: s: singlet, d: doublet, t: triplet, q: quadruplet, m: multiplet, br: broad and coupling 
constants are expressed in Hz. The elemental analyses were performed on a Thermo Finnigan EA 1112 apparatus, both 
at the Service Commun d’Analyses, University of Lorraine, Nancy. 
GENERAL EXPERIMENTAL PROCEDURE 
A mixture of compound 1 (0.01 mol), diamino-alkane (represented in the scheme 1) (0.005 mol) and 4–5 drops of 
glacial acetic acid in ethanol was heated to reflux for 8 h. The resulting solution was cooled to room temperature and the 
precipitated solid was filtered and washed with cold ethanol, then dried to get pure product. 
Spectral Data of New Compounds 
1,3-bis(5-methyl-3-tosyl-1,3,4-triazol-2-onyl)propane (2a).  yield (67%), mpq 130–132 ºC; IR spectrum (ν/cm
-1
): 1711 
(C=O), 1602 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.99 (m, 2H), 2.19 (s, 6H), 2.44 (s, 6H), 3.54 (t, J= 6.9 Hz, 4H), 
7.34-7.97 (2AB(Ts), J=7.8 Hz, 8Harom); 
13
C NMR spectrum (CDCl3): δ (ppm): (150.7, 2C=O), (146.1, 2C=N), (21.2, 
2CH3(Ts)), (11.4, 2CH3), (38.7, 2CH2-N), (26.9, CH2), Carom 127.6-145.5; Anal. Calcd. for C23H26N6O6S2: C, 50.54; H, 
4.79; N, 15.37. Found: C, 50.90; H, 5.00; N, 15.60. 
1,3-bis(5-ethyl-3-tosyl-1,3,4-triazol-2-onyl)propane (2b). yield (57%), mp 136–138 ºC; IR spectrum (ν/cm
-1
): 1709 
(C=O), 1597 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 0.83 (t, J= 7.5Hz, 3H), 1.53 (m, 2H), 1.98 (q, J= 7.5Hz, 4H), 2.28 
(s, 6H), 3.21 (t, J= 6.9 Hz, 4H), 7.39-7.65 (2AB(Ts), J=8.1 Hz, 8Harom); 
13
C NMR spectrum (CDCl3): δ (ppm): (151.4, 
2C=O), (145.4, 2C=N), (21.4, 2CH3(Ts)), (9.0, 2CH3), (13.8, 2CH2), (38.3, 2CH2-N), (26.2, CH2), Carom 127.6-139.0; Anal. 
Calcd. for C25H30N6O6S2: C, 52.25; H, 5.26; N, 14.62. Found: C, 52.50; H, 5.50; N, 14.85. 
1,4-bis(5-methyl-3-tosyl-1,3,4-triazol-2-onyl)butane (2c). yield (55%), mp 260–262 ºC; IR spectrum, ν, cm
-1
: 1716 
(C=O), 1593 (C=N); 
1
H NMR spectrum (DMSO-d6): δ (ppm): 1.44 (m, 4H), 2.16 (s, 6H), 2.41 (s, 6H), 3.47 (m, 4H), 7.45-
7.83 (2AB(Ts), J= 8.1Hz, 8Harom);
13
C NMR spectrum (DMSO-d6): δ (ppm): (151.1, 2C=O), (148.4, 2C=N), (21.0, 
2CH3(Ts)), (11.5, 2CH3), (41.5, 2CH2-N), (24.7, 2CH2), Carom 127.3-145.7; Anal. Calcd. for C24H28N6O6S2: C, 51.42; H, 
5.03; N, 14.99. Found: C, 51.75; H, 5.35; N, 15.30. 
1,4-bis(5-ethyl-3-tosyl-1,3,4-triazol-2-onyl)butane (2d). yield (64%), mp 226-228ºC; IR spectrum (ν/cm
-1
): 1735 (C=O), 
1591 (C=N); 
1
H NMR spectrum (DMSO-d6): δ (ppm): 1.12 (t, J= 7.5Hz, 3H), 1.43 (m, 4H), 2.40 (s, 6H), 2.51 (q, J= 7.5Hz, 
2H), 3.45 (m, 4H), 7.44-7.84 (2AB(Ts), J= 7.8Hz, 8Harom);
13
C NMR spectrum (DMSO-d6): δ (ppm): (152.0, 2C=O), 
(151.3, 2C=N), (9.0, 2CH3), (18.5, 2CH2), (21.0, 2CH3(Ts)), (24.8, 2CH2),  (38.9, 2CH2-N), Carom 127.3-145.7; Anal. 
Calcd. for C26H32N6O6S2: C, 53.05; H, 5.48; N, 14.28. Found: C, 53.05; H, 5.62; N, 13.99. 
1,6-bis(5-methyl-2-tosyl-1,2,4-triazol-3-one-4-yl)hexane (2e). yield (80%), mp 190-192 °C; IR spectrum (ν/cm
-1
): 1722 
(C=O), 1601 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.24 (m, 4H), 1.54 (m, 4H), 2.18 (s, 6H), 2.40 (s, 6H), 3.45 (t, 
J=6.9 Hz, 4H), 7.31-7.93 (2AB(Ts), J= 7.8Hz, 8Harom); 
13
C NMR spectrum (CDCl3): δ (ppm): (151.3, 2C=O), (147.1, 
2C=N), (21.8, 2CH3(Ts)), (12.2, 2CH3), (41.6, 2CH2-N), (28.4, 2CH2), (25.8, 2CH2), Carom 128.2-145.9;  Anal. Calcd. for 
C26H32N6O6S2: C, 53.05; H, 5.48; N, 14.28. Found: C, 53.05; H, 5.62; N, 13.99.  
1,6-bis (5-ethyl-2-tosyl-1,2,4-triazol-3-one-4-yl)hexane (2f). yield (75%), mp 194-196 °C; IR spectrum (ν/cm
-1
): 1735 
(C=O), 1594 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.20 (m, 10H), 1.49 (m, 4H), 2.35 (s, 6H), 2.42 (q, J=7.2 Hz, 4H), 
3.39 (t, J=7.2 Hz, 4H), 7.27- 7.89 (2AB(Ts), J= 8.1 Hz, 8Harom); 
13
C NMR spectrum (CDCl3): δ (ppm): (152.0, 2C=O), 
(151.3, 2C=N), (22.2, 2CH3(Ts)), (19.9, 2CH2-CH3), (10.2, 2CH3-CH2), (41.8, 2CH2-N), (28.8, 2CH2), (26.2, 2CH2), Carom 
128.5-146.2; Anal. Calcd. for C28H36N6O6S2: C, 54.53; H, 5.88; N, 13.63. Found: C, 54.49; H, 5.81, N, 13.42.  
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1,8-bis (5-methyl-2-tosyl-1,2,4-triazol-3-one-4-yl)octane (2g). yield (85%), mp 162-164 °C; IR spectrum (ν/cm
-1
): 1732 
(C=O), 1593 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm):1.00 (m, 4H), 1.38 (m, 4H), 2.11 (s, 6H), 2.31 (s, 6H), 2.43 (m, 
4H), 3.39 (t, J=6.8Hz, 4H), 7.39-7.74 (2AB(Ts), J= 7.9 Hz, 8Harom); 
13
C NMR spectrum (CDCl3): δ (ppm): (151.5, 2C=O), 
(149.1, 2C=N), (21.5, 2CH3(Ts)), (12.0, 2CH3), (41.5, 2CH2-N), (28.6, 2CH2), (28.0, 2CH2), (26.0, 2CH2), Carom 127.8-
146.2; Anal. Calcd for C28H36N6O6S2: C, 54.53; H, 5.88; N, 13.63. Found: C, 54.50; H, 5.82; N, 13.59.  
1,8-bis (5-ethyl-2-tosyl-1,2,4-triazol-3-one-4-yl)octane (2h). yield 82%, mp 174-176 °C; IR spectrum (ν/cm
-1
): 1727 
(C=O), 1588 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.04-1.15 (m, 14H), 1.49 (m, 4H), 2.38(s, 6H), 2.53(q, J=7.5 Hz, 
4H), 3.45(t, J=7.3 Hz, 4H), 7.46-7.82 (2AB(Ts), J= 8.2 Hz, 8Harom);
13
C NMR spectrum (CDCl3): δ (ppm): (151.6, 2C=O), 
(151.0, 2C=N), (21.5, CH3(Ts)), (19.0, 2CH2-CH3), (9.3, 2CH3-CH2), (41.3, 2CH2-N), (28.6, 2CH2), (28.0, 2CH2), (26.0, 
2CH2), Carom 128.1-146.7; Anal. Calcd for C30H40N6O6S2: C, 55.88; H, 6.25; N, 13.03. Found: C, 55.61; H, 6.23; N, 12.92.  
1,10-bis (5-methyl-2-tosyl-1,2,4-triazol-3-one-4-yl)decane (2i). yield (90%), mp 180-182 °C; IR spectrum (ν/cm
-1
): 1736 
(C=O), 1603 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.20-1.28 (m, 12H), 1.54 (m, 4H), 2.18 (s, 6H), 2.40 (s, 6H), 3.45 
(t, J=7.2 Hz, 4H), 7.31-7.93 (2AB(Ts), J= 8.4 Hz, 8Harom);
13
C NMR spectrum (CDCl3): δ (ppm): (151.3, 2C=O), (147.2, 
2C=N), (21.8, 2CH3(Ts)), (12.2, 2CH3), (41.9, 2CH2-N), (29.2, 2CH2), (28.9, 2CH2), (28.6, 2CH2), (26.4, 2CH2), Carom 
128.2-145.9; Anal. Calcd for C30H40N6O6S2: C, 55.88; H, 6.25; N, 13.03. Found: C, 55.57; H, 6.19; N, 12.82.  





H NMR spectrum (CDCl3): δ (ppm): 1.08-1.23 (m, 18H), 1.51 (m, 4H), 2.31-2.48 (m, 10H), 3.41 (t, 
J=6.5 Hz, 4H), 7.26-7.92 (2AB(Ts), J= 7.3 Hz, 8Harom);
13
C NMR spectrum (CDCl3): δ (ppm): (151.6, 2C=O), (150.9, 
2C=N), (21.8, 2CH3(Ts)), (18.2, 2CH2-CH3), (10.9, 2CH3-CH2), (41.9, 2CH2-N), (29.2, 2CH2), (28.9, 2CH2), (28.6, 2CH2), 
(26.4, 2CH2), Carom 128.2-145.6;  Anal. Calcd for C32H44N6O6S2: C, 57.12; H, 6.59; N, 12.49. Found: C, 56.99; H, 6.41; N 
12.32.  
1,12-bis (5-methyl-2-tosyl-1,2,4-triazol-3-one-4-yl)dodecane (2k). yield (87%), mp166-168 °C; IR spectrum (ν/cm
-1
): 
1732 (C=O), 1605 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.14 (m, 16H), 1.50 (m, 4H), 2.14 (s, 6H), 2.36 (s, 6H), 3.41 
(m, 4H), 7.26-7.90 (2AB(Ts), J= 6.9 Hz, 8Harom);
13
C NMR spectrum (CDCl3): δ (ppm): (150.8, 2C=O), (146.6, 2C=N), 
(21.3, 2CH3(Ts)), (11.7, 2CH3), (41.5, 2CH2-N), (28.8, 2CH2), (28.5, 2CH2), (28.5, 2CH2), (28.3, 2CH2), (26.0, 2CH2), 
Carom 127.7-145.3;  Anal. Calcd for C32H44N6O6S2: C, 57.12; H, 6.59; N, 12.49. Found: C, 57.11; H, 6.61; N; 12.58. 
1,12-bis (5-ethyl-2-tosyl-1,2,4-triazol-3-one-4-yl)dodecane (2l). yield (47%), mp166-168 °C; IR spectrum (ν/cm
-1
): 1730 
(C=O), 1607 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 0.98 (t, J= 7.5Hz, 3H),1.59 (m, 16H), 2.10 (q, J= 7.5Hz, 2H), 2.37 
(s, 6H), 2.80 (m, 4H), 4.66 (m, 4H), 7.31-7.79 (2AB(Ts), J= 8.1 Hz, 8Harom); Anal. Calcd for C32H44N6O6S2: C, 57.12; H, 
6.59; N, 12.49. Found: C, 57.11; H, 6.61; N; 12.58. 
1,2-bis(5-methyl-3-tosyl-1,3,4-triazol-2-onyl)cyclohexane (2m). yield (60%), mp 180-182ºC; IR spectrum (ν/cm
-1
): 1721 
(C=O), 1585 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm):  1.36 (m, 4H), 1.76 (m, 4H), 2.00 (s, 6H), 2.45 (s, 6H), 4.63 (t, J= 
6.3 Hz, 2H), 7.33-7.82 (2AB(Ts), J= 8.1, 8Harom);
13
C NMR spectrum (CDCl3): δ (ppm): (150.4, 2C=O), (146.9, 2C=N), 
(11.2, 2CH3), (21.7, 2CH3(Ts)), (24.4, 2CH2), (29.2, 2CH2), (53.5, 2CH-N), Carom 127.5-145.6;  Anal. Calcd. for 
C26H30N6O6S2: C, 53.23; H, 5.25; N, 14.32. Found: C, 53.05; H, 5.62; N, 13.99. 
1,2-bis(5-éthyl-3-tosyl-1,3,4-triazol-2-onyl)cyclohexane (2n). yield (30%), mp 190-192ºC; IR spectrum (ν/cm
-1
): 1718 
(C=O), 1595 (C=N); 
1
H NMR spectrum (CDCl3): δ (ppm): 1.09 (t, J= 7.5Hz, 6H), 1.18 (m, 4H), 1.57 (m, 4H), 1.97 (q, J= 
7.5Hz, 2H), 2.23 (s, 6H), 3.97 (t, J= 6.9 Hz, 2H), 7.42-7.67 (2AB(Ts), J= 8.1, 8Harom);
13
C NMR spectrum (CDCl3): δ 
(ppm): (151.7, 2C=O), (148.6, 2C=N), (8.9, 2CH3), (14.3, 2CH2), (21.3, 2CH3(Ts)), (29.2, 2CH2), (42.4, 2CH2), (61.4, 2CH-
N), Carom 123.9-143.4; Anal. Calcd. for C28H34N6O6S2: C, 54.71; H, 5.57; N, 13.67. Found: C, 54.49; H, 5.81, N, 13.42. 
ACKNOWLEDGMENTS 
Thanks are due to the Ministry of Higher Education and Scientific Research and Technology in Tunisia and 
University of Sfax for financial support. 
 
REFERENCES 
[1] F. F. Barsoum, H. M. Hosni, A. S. Girgis, Bioorg. Med. Chem. 14(2006) 3929. 
[2] L. G. Mardenborough, X. Y. Zhu, P. Fan, M. R. Jacob, S. L. Khan, L. A. Walker, S. Y. Ablordeppey, Bioorg. Med. 
Chem. 13(2005) 3955. 
[3]  M. P. Gajewski, H. Beall, M. Schnieder, S. M. Stranahan, M. D. Mosher, K. C. Rider, N. R. Natale, Bioorg. Med. Chem. 
Lett. 19 (2009) 4067. 
[4] M. A. Ali, M. Shaharyar, Bioorg. Med. Chem. Lett. 17(2007)  3314. 
ISSN 2321-807X 
2181 | P a g e                                                           J u n e  0 9 ,  2 0 1 4  
[5] I. Stolić, K. Mišković, A. Magdaleno, A. M. Silber, I. Piantanda, M. Bajić, L. Glavaš-Obrovac, Bioorg. Med. Chem. 
17(2009) 2544. 
[6] R. Filosa, A. Peduto, S. Di Micco, P. De Caprariis, M. Festa, A. Petrella, G. Capranico, G. Bifulco, Bioorg. Med. Chem. 
17(2009) 13. 
[7] N. Kode, L. Chen, D. Murthy, D. Adewumi, S. Phadtare, Eur. J. Med. Chem. 42(2007)  327. 
[8] D. Maciejewska, M. Rasztawicka, I. Wolska, E. Anuszewska, B. Gruber, Eur. J. Med. Chem. 44 (2009) 4136. 
[9] Y-H. Yang, M-S. Cheng, Q-H. Wang, H. Nie, N. Liao, J. Wang, H. Chen, Eur. J. Med. Chem. 44 (2009) 1808. 
[10] P. Palit, P. Paira, A. Hazra, S. Banerjee, A. Das Gupta, S. G. Dastidar, N. B. Mondal, Eur. J. Med. Chem. 44(2009) 
845. 
[11] M. M. Ghorab, A. M. Sh. El-Sharief, Y. A. Ammar, Sh. I. Mohamed, Il Farmaco. 55 (2000) 354. 
[12] B. S. Holla, K. N. Poojary, B. S. Rao, M. K. Shivananda, Eur. J. Med. Chem. 37 (2002) 511. 
[13] G. Q. Hu, S. Q. Xie, W. L. Huang, Chin. Chem. Lett. 18 (2007) 124. 
[14] M. Damodiran, D. Muralidharan, P. T. Perumal, Bioorg. Med. Chem. Lett. 19 (2009) 3611-3614. 
[15]  V. S. Palekar, A. J. Damle, S. R. Shukla, Eur. J. Med. Chem. 44 (2009) 5112. 
[16] S. Han, F-F. Zhang, X. Xie, J-Z. Chen, Eur. J. Med. Chem. 74 (2014) 73. 
[17]  H. Bayrak, A. Demirbas, N. Demirbas, S- A. Karaoglu, Eur. J. Med. Chem. 45 (2010) 4726. 
[18] N. Fischer, K. Hüll, Th. M. Klapötke, J. Stierstorfer, J. Heterocyclic Chem. 51 (2014)  85. 
[19]  S. Hamzaoui, A. Ben Salem, A. Ben Hsouna, N. Chaari, M. Trigui, M. Mourer, M. Kossentini, MedJChem. 5 (2012) 
246. 
[20]  B. Ben Salah, N. Chaari, A. Rekik, A. Ben Hsouna, M. Trigui, M. Kossentini, J. Heterocyclic Chem. (2014), in press, 
Corrected Proof.
 
